CPHI 2025: Redefining Nutraceuticals with New Delivery Formats and Pharma-Grade Standards
The line between pharmaceuticals and nutraceuticals is increasingly becoming indistinct. At CPHI 2025, innovations that blend efficacy and formats from both sectors were prominently showcased.
Industry Convergence and New Delivery Formats
On the showroom floor, Nutrition Insight engaged with PharmaLinea, Lubrizol, Sirio, Corbion, and Bioiberica to explore the merging paths of these industries.
PharmaLinea’s Perspective on Industry Standards
Matevž Ambrožič, marketing director at PharmaLinea, said: “They have substantial marketing power and are applying pressure to the supplement industry to develop higher quality and proof of efficacy.”
He emphasized that the pharmaceutical sector is pushing the supplement industry toward adopting their higher standards.
Advancing Clinical Substantiation
PharmaLinea prioritizes clinical validation as vital for achieving pharmaceutical-grade supplements. Ambrožič explained:
“While branded ingredients are increasingly backed by clinical studies, finished-product clinical validation is still rare — and that’s where we focus.”
The company already has multiple product lines clinically tested at the finished-product level and maintains a robust pipeline of upcoming trials. Their aim is to clinically substantiate their entire portfolio.
“That’s our way of adapting to the future that will probably be more pharmaceutical-grade standards — at least for a part of the supplement industry.”
Author’s Summary
CPHI 2025 highlights the growing fusion of pharmaceuticals and nutraceuticals, with companies like PharmaLinea driving clinical validation to elevate supplement standards.